US FDA-approval of VAMOROLONE for Duchenne Muscular Dystrophy (DMD)*-a novel alternative steroid with unique properties. New Drugs and Therapeutics On October 26, 2023, the US…
Read MoreLUPRON DEPOT-PED 45 mg for 6 months Prepared and edited on behalf of the PES Drug & Therapeutics committee: Shilpa Mehta, MD, Amit Lahoti, MD, Aditi…
Read MoreNew Drugs and Therapeutics Update – NGENLA By Dania Al-Hamad, MD, and Christine Yu, MD NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog, was approved…
Read MoreBrief Therapeutic Update from PES Drugs and Therapeutics Committee Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide) Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide)…
Read MoreNew Meds and Tech from PES Drugs and Therapeutics committee Palovarotene (SohonosTM – Ipsen Pharmaceuticals Inc.) By: Ambika Ashraf, MD and Anna Ryabets-Lienhard, DO Update:…
Read MoreBrief Therapeutic Update from PES Drugs and Therapeutics Committee iLet ® Bionic Pancreas On May 19, 2023, the U.S. Food and Drug Administration approved the…
Read MoreBrief Therapeutic Update from PES Drugs and Therapeutics Committee Sogroya® (somapactian) Once weekly Sogroya® (somapacitan-beco, Novo Nordisk) was approved by the United States Food and Drug…
Read MoreBrief Therapeutic Update from PES Drugs and Therapeutics Committee The MiniMed™780G System The MiniMed 780G System from Medtronic was approved by the US Food and Drug…
Read MoreDexcom G7 In December 2022, the Dexcom G7 continuous glucose monitor system was cleared by the FDA for use in people age 2 and older…
Read MoreWegovy® (semaglutide) once weekly injection is a glucagon-like peptide 1 receptor agonist (GLP1-RA) approved by the FDA in June, 2021 for weight management in adults. Wegovy…
Read More